💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sumatriptan Succinate

CHEMBL1201150 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
413.5 g/mol
LogP
—
Phase
4

A succinate salt form of sumatriptan with the same therapeutic properties. Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size.

분자량

413.5000 g/mol

TPSA

148.00 Ų

치료 영역

Pain Management Migraine Chronic Pain

작용 기전

Selective 5-HT1B/1D receptor agonist.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Selective 5-HT1B/1D receptor agonist.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H27N3O6S

                    

                    
                    

                        
HBD / HBA

                        
4 / 8

                    

                    
                    

                        
회전 가능 결합

                        
9

                    

                    
                    
                    

                        
무거운 원자

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
A succinate salt form of sumatriptan with the same therapeutic properties. Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective 5-HT1B/1D receptor agonist.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Sumatriptan Succinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201150.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 59772.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.